Physician profile
Rena Ali
NPI 1679116966
$10,852.67
in general payments reported to CMS, 2019-2025
29 companies · $3,852 in 2025
The $3,852 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,122 · 2022: $600 · 2023: $1,224 · 2024: $3,055 · 2025: $3,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,381 · Consulting Fee: $1,725 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,381.27 |
| Consulting Fee | $1,725.00 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,805.67 | 2021-2025 | |
| Coloplast Corp | $1,252.45 | 2023-2025 | Titan |
| Novo Nordisk INC | $1,056.92 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,039.49 | 2021 | |
| Gilead Sciences, INC. | $966.07 | 2022-2024 | Descovy, Livdelzi |
| Viiv Healthcare Company | $725.89 | 2022-2025 | Apretude |
| Madrigal Pharmaceuticals | $714.15 | 2025 | Rezdiffra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $340.26 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.33 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $288.28 | 2025 | Voquezna |
| Ardelyx, INC. | $253.71 | 2025 | Ibsrela |
| Amgen INC. | $230.13 | 2025 | Krystexxa, Repatha |
| Sanofi Pasteur INC. | $226.90 | 2024 | |
| Sanofi-Aventis U.S. LLC | $169.98 | 2024 | |
| Genzyme Corporation | $146.18 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $145.07 | 2022 | |
| Bridgebio Pharma, INC. | $133.45 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $129.58 | 2021-2024 | Farxiga |
| Medtronic, INC. | $127.50 | 2025 | Venaseal |
| Otsuka America Pharmaceutical, INC. | $124.01 | 2024 | |
| Pfizer INC. | $120.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.58 | 2025 | Entyvio |
| Grifols USA, LLC | $117.07 | 2024 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $113.92 | 2025 | |
| Idorsia Pharmaceuticals US INC | $98.56 | 2023 | Quviviq |
| Exact Sciences Corporation | $49.03 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $30.91 | 2024 | Veozah |
| Lilly USA, LLC | $20.32 | 2025 | Zepbound |
| Phadia US INC. | $16.99 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.